Patients with diabetes often experience foot complications, such as ulcers, infections, and even amputations.1
Adverse drug events are an important factor influencing health outcomes of individuals treated with psychotropic medications.
Many nonpsychiatric medications have the potential to cause neuropsychiatric events ranging from anxiety to psychosis.
Treatment options include lifestyle modifications, psychotherapy, and pharmacotherapy.
Psychopathy is a serious personality disorder that can have significant negative effects both on individuals and on society.
It is often the behavioral symptoms associated with disease progression that lead to hospitalization.
Depending upon the severity of symptoms, patients may be treated in the inpatient or outpatient setting.
This agent may be an alternative for patients with pain severe enough to require around-the-clock, long-term opioid therapy when other options are inadequate.
Through screening for early detection of cognitive impairment and dementia, patients have a better chance of managing their diabetes at home with provider assistance.
The proposed rule will replace existing regulations and provide detailed, current information for patients and their providers.
This article reviews five new drugs (umeclidinium and vilanterol, vortioxetine, dapagliflozin, luliconazole, sofosbuvir) that were approved by the FDA in the past year.
Five new molecular entities (riociguat, ibrutinib, obinutuzumab, coagulation factor XIII A-subunit [recombinant], collagenase clostridium histolyticum) that were recently approved by the FDA are discussed.
New guidelines recommend chemoprevention (tamoxifen or raloxifene) for high-risk patients.
Women are underrepresented and gender-specific analysis is uncommon in most clinical trials.
It has been suggested that physicians may be misdiagnosing women more often because their symptoms may differ from those experienced by men.
In this innovative practice model, pharmacists collaborate with women's health providers to educate patients.
Surgical techniques are directed at decreasing pain, discomfort, and complications.
Managing fluid and electrolytes, anemia, and mineral metabolism is key to optimizing therapy.
There are no testosterone pills, patches, or gels currently approved by the FDA for treating sexual dysfunction in women.
A number of medications have been proposed as possible causes of drug-induced urinary incontinence, including alpha1
-adrenoceptor antagonists, antipsychotics, benzodiazepines, antidepressants, and hormone replacement therapy.
For more articles, please check our archives.